Pharmaceutical formulations comprising an insulin derivative
US9034818B2 · kind B2 · utility
7Cited by
30References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 12, 2008 |
| Grant date | May 19, 2015 |
| Priority date | — |
| Expiry date | Jun 12, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/62
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns a soluble pharmaceutical formulation comprising an insulin derivative wherein the formulation further comprises more than 4 zinc atoms per 6 molecules of the insulin derivative, and a citric acid monohydrate and/or a histidine compound used in an amount sufficient to increase the tendency of the insulin derivative to self-associate into dodecamers. The invention further comprises a process for preparing the soluble pharmaceutical formulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.